Zimmer Biomet (NYSE:ZBH) Price Target Raised to $98.00 at Citigroup

Zimmer Biomet (NYSE:ZBH) had its price objective raised by Citigroup from $94.00 to $98.00 in a research note issued to investors on Wednesday, MarketBeat reports. The firm currently has a neutral rating on the medical equipment provider’s stock.

A number of other analysts also recently issued reports on ZBH. Royal Bank Of Canada dropped their price target on shares of Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating on the stock in a report on Thursday, November 6th. BTIG Research reaffirmed a “buy” rating and issued a $112.00 price objective on shares of Zimmer Biomet in a report on Tuesday. TD Cowen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Monday, January 26th. Evercore raised shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and raised their price objective for the stock from $94.00 to $120.00 in a research note on Monday, January 5th. Finally, Robert W. Baird reissued a “neutral” rating and issued a $100.00 price objective (down previously from $117.00) on shares of Zimmer Biomet in a research note on Tuesday, December 16th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, nine have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and an average target price of $106.20.

Zimmer Biomet Stock Up 1.3%

ZBH traded up $1.23 during midday trading on Wednesday, hitting $96.84. The company had a trading volume of 508,181 shares, compared to its average volume of 2,343,494. The stock’s 50 day moving average price is $90.01 and its 200 day moving average price is $95.64. The company has a quick ratio of 1.39, a current ratio of 1.98 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $19.19 billion, a price-to-earnings ratio of 27.30, a PEG ratio of 2.34 and a beta of 0.62. Zimmer Biomet has a 52 week low of $84.59 and a 52 week high of $114.44.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. The company had revenue of $2.24 billion during the quarter, compared to analyst estimates of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. Zimmer Biomet’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same period in the prior year, the business posted $2.31 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, research analysts anticipate that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th were paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.0%. The ex-dividend date was Tuesday, December 30th. Zimmer Biomet’s dividend payout ratio is currently 27.12%.

Institutional Investors Weigh In On Zimmer Biomet

Several hedge funds have recently made changes to their positions in the business. Legacy Wealth Asset Management LLC raised its stake in Zimmer Biomet by 2.3% during the 3rd quarter. Legacy Wealth Asset Management LLC now owns 4,670 shares of the medical equipment provider’s stock valued at $460,000 after acquiring an additional 106 shares during the last quarter. Global Retirement Partners LLC increased its holdings in shares of Zimmer Biomet by 7.0% in the third quarter. Global Retirement Partners LLC now owns 1,686 shares of the medical equipment provider’s stock valued at $166,000 after purchasing an additional 111 shares during the period. Main Management ETF Advisors LLC raised its stake in shares of Zimmer Biomet by 1.0% during the fourth quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider’s stock worth $986,000 after purchasing an additional 112 shares during the last quarter. Cullen Frost Bankers Inc. lifted its holdings in shares of Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 116 shares during the period. Finally, Generali Asset Management SPA SGR grew its position in Zimmer Biomet by 0.9% in the 3rd quarter. Generali Asset Management SPA SGR now owns 14,232 shares of the medical equipment provider’s stock valued at $1,402,000 after buying an additional 122 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet News Roundup

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q4 beat and buyback: ZBH reported Q4 EPS of $2.42 and revenue up ~11% YoY, beating estimates; management also announced a new share buyback, which together drove the immediate market rally. Zimmer Biomet (ZBH) Is Up 6.1% After Earnings Beat And New Buyback Plan Is Announced
• Positive Sentiment: Analyst upgrade/positive call: BTIG reaffirmed a Buy and set a $112 price target, signaling conviction that the company’s orthopedic demand and margin recovery story have upside. Zimmer Biomet (NYSE:ZBH) Earns “Buy” Rating from BTIG Research
• Neutral Sentiment: Broker price target tweaks but cautious stance: Citigroup and Wells Fargo nudged their price targets to $98 while keeping neutral/equal-weight recommendations, implying only modest upside from current levels. Benzinga coverage of analyst price target changes
• Neutral Sentiment: Needham reaffirms Hold: Needham kept its Hold rating, reflecting mixed views on medium-term upside despite recent top-line strength. Needham & Company LLC Reaffirms “Hold” Rating for Zimmer Biomet (NYSE:ZBH)
• Negative Sentiment: Cautious guidance, margin pressure and operational reset risks: Management issued measured 2026 guidance and noted a U.S. salesforce overhaul that could weigh on near-term growth and margins; tariffs and margin contraction were called out as headwinds by analysts and in earnings commentary. ZBH Q4 Deep Dive: U.S. Salesforce Overhaul Drives Guidance Caution Amid Product Momentum

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.